Cross-Sector entity
Bundibugyo ebolavirus is most often covered alongside ACOREP, which appears in 2 of these 3 stories. The clearest coverage concentration is clinical-trial: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 3.7 original sources on average.
3 verified stories tracked
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bundibugyo ebolavirus is most often covered alongside ACOREP, which appears in 2 of these 3 stories. The clearest coverage concentration is clinical-trial: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 3.7 original sources on average. This profile follows 3 Cross-Sector stories mentioning Bundibugyo ebolavirus across the period from July 11, 2026 to July 13, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bundibugyo ebolavirus. Shared-story counts are live from our verified record — not editorial picks.
Ethics Approval Received
NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
Outbreak Worsens
DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
Africa CDC declares fastest-growing outbreak
Africa CDC states the outbreak is the fastest-growing Ebola epidemic on the continent as news of the spread to new provinces circulates.
Health workers protest
Ebola response workers protest outside three treatment centers in Bunia over unpaid wages; police disperse one demonstration at CME.
Government report released
A government report published late Wednesday confirms 1,759 total cases and 600 deaths, with two new suspected cases in Kisangani, Tshopo province—one with no known epidemiological link.
Clinical trials scheduled
Health workers prepare for Ebola clinical trials at the Evangelical Medical Center in Bunia, Ituri province.
Outbreak declared
DRC authorities declare a new Ebola outbreak caused by the Bundibugyo virus, after weeks of undetected transmission according to WHO.
As the DRC Ebola outbreak surpasses 1,900 cases with 702 fatalities, NanoViricides’ oral NV-387 gummies gain ethics approval for a Phase II trial. The chewable format could overcome logistical hurdles in resource-limited regions, potentially reshaping epidemic management if proven effective.
NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.
Source: newjerseytelegraph.com · hawaiitelegraph.com
The public health crisis deepens as Ebola spreads to previously unaffected areas, with response hampered by funding gaps, worker protests, and no approved countermeasures.
Source: sconeadvocate.com.au · timesfreepress.com
